Effects of macitentan and tadalafil monotherapy or their combination on the right ventricle and plasma metabolites in pulmonary hypertensive rats

Pulmonary arterial hypertension is a severe respiratory disease characterized by pulmonary artery remodeling. RV dysfunction and dysregulated circulating metabolomics are associated with adverse outcomes in pulmonary arterial hypertension. We investigated effects of tadalafil and macitentan alone or...

Full description

Bibliographic Details
Main Authors: Argen Mamazhakypov, Astrid Weiß, Sven Zukunft, Akylbek Sydykov, Baktybek Kojonazarov, Jochen Wilhelm, Christina Vroom, Aleksandar Petrovic, Djuro Kosanovic, Norbert Weissmann, Werner Seeger, Ingrid Fleming, Marc Iglarz, Friedrich Grimminger, Hossein A. Ghofrani, Soni S. Pullamsetti, Ralph T. Schermuly
Format: Article
Language:English
Published: SAGE Publishing 2020-11-01
Series:Pulmonary Circulation
Online Access:https://doi.org/10.1177/2045894020947283
id doaj-f12a5a6e63d44ffdb2021cbce29d7c48
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Argen Mamazhakypov
Astrid Weiß
Sven Zukunft
Akylbek Sydykov
Baktybek Kojonazarov
Jochen Wilhelm
Christina Vroom
Aleksandar Petrovic
Djuro Kosanovic
Norbert Weissmann
Werner Seeger
Ingrid Fleming
Marc Iglarz
Friedrich Grimminger
Hossein A. Ghofrani
Soni S. Pullamsetti
Ralph T. Schermuly
spellingShingle Argen Mamazhakypov
Astrid Weiß
Sven Zukunft
Akylbek Sydykov
Baktybek Kojonazarov
Jochen Wilhelm
Christina Vroom
Aleksandar Petrovic
Djuro Kosanovic
Norbert Weissmann
Werner Seeger
Ingrid Fleming
Marc Iglarz
Friedrich Grimminger
Hossein A. Ghofrani
Soni S. Pullamsetti
Ralph T. Schermuly
Effects of macitentan and tadalafil monotherapy or their combination on the right ventricle and plasma metabolites in pulmonary hypertensive rats
Pulmonary Circulation
author_facet Argen Mamazhakypov
Astrid Weiß
Sven Zukunft
Akylbek Sydykov
Baktybek Kojonazarov
Jochen Wilhelm
Christina Vroom
Aleksandar Petrovic
Djuro Kosanovic
Norbert Weissmann
Werner Seeger
Ingrid Fleming
Marc Iglarz
Friedrich Grimminger
Hossein A. Ghofrani
Soni S. Pullamsetti
Ralph T. Schermuly
author_sort Argen Mamazhakypov
title Effects of macitentan and tadalafil monotherapy or their combination on the right ventricle and plasma metabolites in pulmonary hypertensive rats
title_short Effects of macitentan and tadalafil monotherapy or their combination on the right ventricle and plasma metabolites in pulmonary hypertensive rats
title_full Effects of macitentan and tadalafil monotherapy or their combination on the right ventricle and plasma metabolites in pulmonary hypertensive rats
title_fullStr Effects of macitentan and tadalafil monotherapy or their combination on the right ventricle and plasma metabolites in pulmonary hypertensive rats
title_full_unstemmed Effects of macitentan and tadalafil monotherapy or their combination on the right ventricle and plasma metabolites in pulmonary hypertensive rats
title_sort effects of macitentan and tadalafil monotherapy or their combination on the right ventricle and plasma metabolites in pulmonary hypertensive rats
publisher SAGE Publishing
series Pulmonary Circulation
issn 2045-8940
publishDate 2020-11-01
description Pulmonary arterial hypertension is a severe respiratory disease characterized by pulmonary artery remodeling. RV dysfunction and dysregulated circulating metabolomics are associated with adverse outcomes in pulmonary arterial hypertension. We investigated effects of tadalafil and macitentan alone or in combination on the RV and plasma metabolomics in SuHx and PAB models. For SuHx model, rats were injected with SU5416 and exposed to hypoxia for three weeks and then were returned to normoxia and treated with either tadalafil (10 mg/kg in chow) or macitentan (10 mg/kg in chow) or their combination (both 10 mg/kg in chow) for two weeks. For PAB model, rats were subjected to either sham or PAB surgery for three weeks and treated with above-mentioned drugs from week 1 to week 3. Following terminal echocardiographic and hemodynamic measurements, tissue samples were collected for metabolomic, histological and gene expression analysis. Both SuHx and PAB rats developed RV remodeling/dysfunction with severe and mild plasma metabolomic alterations, respectively. In SuHx rats, tadalafil and macitentan alone or in combination improved RV remodeling/function with the effects of macitentan and combination therapy being superior to tadalafil. All therapies similarly attenuated SuHx-induced changes in plasma metabolomics. In PAB rats, only macitentan improved RV remodeling/function, while only tadalafil attenuated PAB-induced changes in plasma metabolomics.
url https://doi.org/10.1177/2045894020947283
work_keys_str_mv AT argenmamazhakypov effectsofmacitentanandtadalafilmonotherapyortheircombinationontherightventricleandplasmametabolitesinpulmonaryhypertensiverats
AT astridweiß effectsofmacitentanandtadalafilmonotherapyortheircombinationontherightventricleandplasmametabolitesinpulmonaryhypertensiverats
AT svenzukunft effectsofmacitentanandtadalafilmonotherapyortheircombinationontherightventricleandplasmametabolitesinpulmonaryhypertensiverats
AT akylbeksydykov effectsofmacitentanandtadalafilmonotherapyortheircombinationontherightventricleandplasmametabolitesinpulmonaryhypertensiverats
AT baktybekkojonazarov effectsofmacitentanandtadalafilmonotherapyortheircombinationontherightventricleandplasmametabolitesinpulmonaryhypertensiverats
AT jochenwilhelm effectsofmacitentanandtadalafilmonotherapyortheircombinationontherightventricleandplasmametabolitesinpulmonaryhypertensiverats
AT christinavroom effectsofmacitentanandtadalafilmonotherapyortheircombinationontherightventricleandplasmametabolitesinpulmonaryhypertensiverats
AT aleksandarpetrovic effectsofmacitentanandtadalafilmonotherapyortheircombinationontherightventricleandplasmametabolitesinpulmonaryhypertensiverats
AT djurokosanovic effectsofmacitentanandtadalafilmonotherapyortheircombinationontherightventricleandplasmametabolitesinpulmonaryhypertensiverats
AT norbertweissmann effectsofmacitentanandtadalafilmonotherapyortheircombinationontherightventricleandplasmametabolitesinpulmonaryhypertensiverats
AT wernerseeger effectsofmacitentanandtadalafilmonotherapyortheircombinationontherightventricleandplasmametabolitesinpulmonaryhypertensiverats
AT ingridfleming effectsofmacitentanandtadalafilmonotherapyortheircombinationontherightventricleandplasmametabolitesinpulmonaryhypertensiverats
AT marciglarz effectsofmacitentanandtadalafilmonotherapyortheircombinationontherightventricleandplasmametabolitesinpulmonaryhypertensiverats
AT friedrichgrimminger effectsofmacitentanandtadalafilmonotherapyortheircombinationontherightventricleandplasmametabolitesinpulmonaryhypertensiverats
AT hosseinaghofrani effectsofmacitentanandtadalafilmonotherapyortheircombinationontherightventricleandplasmametabolitesinpulmonaryhypertensiverats
AT sonispullamsetti effectsofmacitentanandtadalafilmonotherapyortheircombinationontherightventricleandplasmametabolitesinpulmonaryhypertensiverats
AT ralphtschermuly effectsofmacitentanandtadalafilmonotherapyortheircombinationontherightventricleandplasmametabolitesinpulmonaryhypertensiverats
_version_ 1724424544631914496
spelling doaj-f12a5a6e63d44ffdb2021cbce29d7c482020-11-25T04:08:40ZengSAGE PublishingPulmonary Circulation2045-89402020-11-011010.1177/2045894020947283Effects of macitentan and tadalafil monotherapy or their combination on the right ventricle and plasma metabolites in pulmonary hypertensive ratsArgen Mamazhakypov0Astrid Weiß1Sven Zukunft2Akylbek Sydykov3Baktybek Kojonazarov4Jochen Wilhelm5Christina Vroom6Aleksandar Petrovic7Djuro Kosanovic8Norbert Weissmann9Werner Seeger10Ingrid Fleming11Marc Iglarz12Friedrich Grimminger13Hossein A. Ghofrani14Soni S. Pullamsetti15Ralph T. Schermuly16Cardio-Pulmonary Institute (CPI), Universities of Giessen and Marburg Lung Center, Member of the German Lung Center (DZL), Justus-Liebig-University Giessen, Giessen, GermanyCardio-Pulmonary Institute (CPI), Universities of Giessen and Marburg Lung Center, Member of the German Lung Center (DZL), Justus-Liebig-University Giessen, Giessen, GermanyInstitute for Vascular Signalling, Centre for Molecular Medicine, Goethe University, Frankfurt am Main, Germany & German Center of Cardiovascular Research (DZHK), Partner site RheinMain, Frankfurt am Main, GermanyCardio-Pulmonary Institute (CPI), Universities of Giessen and Marburg Lung Center, Member of the German Lung Center (DZL), Justus-Liebig-University Giessen, Giessen, GermanyCardio-Pulmonary Institute (CPI), Universities of Giessen and Marburg Lung Center, Member of the German Lung Center (DZL), Justus-Liebig-University Giessen, Giessen, GermanyCardio-Pulmonary Institute (CPI), Universities of Giessen and Marburg Lung Center, Member of the German Lung Center (DZL), Justus-Liebig-University Giessen, Giessen, GermanyCardio-Pulmonary Institute (CPI), Universities of Giessen and Marburg Lung Center, Member of the German Lung Center (DZL), Justus-Liebig-University Giessen, Giessen, GermanyCardio-Pulmonary Institute (CPI), Universities of Giessen and Marburg Lung Center, Member of the German Lung Center (DZL), Justus-Liebig-University Giessen, Giessen, GermanySechenov First Moscow State Medical University (Sechenov University), Moscow, RussiaCardio-Pulmonary Institute (CPI), Universities of Giessen and Marburg Lung Center, Member of the German Lung Center (DZL), Justus-Liebig-University Giessen, Giessen, GermanyDepartment of Lung Development and Remodelling, Max-Planck Institute for Heart and Lung Research, Bad Nauheim, GermanyInstitute for Vascular Signalling, Centre for Molecular Medicine, Goethe University, Frankfurt am Main, Germany & German Center of Cardiovascular Research (DZHK), Partner site RheinMain, Frankfurt am Main, GermanyActelion Pharmaceuticals Ltd, Allschwil, SwitzerlandCardio-Pulmonary Institute (CPI), Universities of Giessen and Marburg Lung Center, Member of the German Lung Center (DZL), Justus-Liebig-University Giessen, Giessen, GermanyCardio-Pulmonary Institute (CPI), Universities of Giessen and Marburg Lung Center, Member of the German Lung Center (DZL), Justus-Liebig-University Giessen, Giessen, GermanyDepartment of Lung Development and Remodelling, Max-Planck Institute for Heart and Lung Research, Bad Nauheim, GermanyCardio-Pulmonary Institute (CPI), Universities of Giessen and Marburg Lung Center, Member of the German Lung Center (DZL), Justus-Liebig-University Giessen, Giessen, GermanyPulmonary arterial hypertension is a severe respiratory disease characterized by pulmonary artery remodeling. RV dysfunction and dysregulated circulating metabolomics are associated with adverse outcomes in pulmonary arterial hypertension. We investigated effects of tadalafil and macitentan alone or in combination on the RV and plasma metabolomics in SuHx and PAB models. For SuHx model, rats were injected with SU5416 and exposed to hypoxia for three weeks and then were returned to normoxia and treated with either tadalafil (10 mg/kg in chow) or macitentan (10 mg/kg in chow) or their combination (both 10 mg/kg in chow) for two weeks. For PAB model, rats were subjected to either sham or PAB surgery for three weeks and treated with above-mentioned drugs from week 1 to week 3. Following terminal echocardiographic and hemodynamic measurements, tissue samples were collected for metabolomic, histological and gene expression analysis. Both SuHx and PAB rats developed RV remodeling/dysfunction with severe and mild plasma metabolomic alterations, respectively. In SuHx rats, tadalafil and macitentan alone or in combination improved RV remodeling/function with the effects of macitentan and combination therapy being superior to tadalafil. All therapies similarly attenuated SuHx-induced changes in plasma metabolomics. In PAB rats, only macitentan improved RV remodeling/function, while only tadalafil attenuated PAB-induced changes in plasma metabolomics.https://doi.org/10.1177/2045894020947283